Your privacy is very important for us. When you visit our website, please agree to the use of all cookies. For more information about the processing of personal data, please go to Privacy Policy

Contact
July 30,2026

TrueLab Biopharmaceutical Announces Completion of Enrollment for the Phase 1 SAD Part of TL-003

BACK
BACK
SHARE
SHARE

China – July 30, 2026, TrueLab Biopharmaceutical, an immunology-driven innovator leveraging a proprietary, AI-powered R&D platform to develop transformative therapies for immune-mediated inflammatory diseases, today announced the completion of enrollment for the Phase 1 SAD Part (NCT07526519) of TL-003, an anti-TL1A×IL23p19 bispecific antibody.

NEXT POST

No more